MANAGEMENT
chief executive officer & Chief Financial Officer Ronny Skuggedal
Mr. Skuggedal joined PCI Biotech in October 2013 as CFO with responsibility for finance, accounting and investor relations, and with a key role in business development. Ronny was appointed Interim CEO effective 1st June 2022, and promoted to CEO effective 1st September 2022. He holds a Master of Science in Economics and Business Administration from the Norwegian School of Economics (NHH) and a Master in Professional Accountancy from BI Norwegian Business School. Before joining PCI Biotech, he was a Director at PwC within Assurance and he has twelve years of experience from auditing and advisory services.
Chief Scientific Officer Morten luhr, PhD
Morten Luhr joined PCI Biotech in 2021, contributing to both business development and R&D efforts in advancing the photochemical internalisation (PCI) technology and the more recent photochemical lysis (PCL) technology. He holds a Ph.D. in cell biology from the University of Oslo, where he specialised in autophagy and the unfolded protein response. As a Fulbright Scholar, he conducted research at Harvard Medical School, further deepening his expertise in cell biology. Before PCI Biotech, Morten held the role as Lead Scientist in development of the Gibco CTS DynaCellect Magnetic Separation System at Thermo Fisher Scientific, a solution for automated T-cell manufacturing. He has co-authored several academic publications and is inventor on multiple patent applications.